CA2719749A1 - Methods for treating disorders using nmda nr2b-subtype selective antagonist - Google Patents

Methods for treating disorders using nmda nr2b-subtype selective antagonist Download PDF

Info

Publication number
CA2719749A1
CA2719749A1 CA2719749A CA2719749A CA2719749A1 CA 2719749 A1 CA2719749 A1 CA 2719749A1 CA 2719749 A CA2719749 A CA 2719749A CA 2719749 A CA2719749 A CA 2719749A CA 2719749 A1 CA2719749 A1 CA 2719749A1
Authority
CA
Canada
Prior art keywords
pain
disease
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2719749A
Other languages
English (en)
French (fr)
Inventor
John Alan Kemp
Timothy Tasker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec International GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of CA2719749A1 publication Critical patent/CA2719749A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2719749A 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist Abandoned CA2719749A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4008708P 2008-03-27 2008-03-27
US61/040,087 2008-03-27
PCT/EP2009/002241 WO2009118187A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Publications (1)

Publication Number Publication Date
CA2719749A1 true CA2719749A1 (en) 2009-10-01

Family

ID=40910288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2719749A Abandoned CA2719749A1 (en) 2008-03-27 2009-03-26 Methods for treating disorders using nmda nr2b-subtype selective antagonist

Country Status (14)

Country Link
US (1) US20110053951A1 (https=)
EP (1) EP2254580A1 (https=)
JP (3) JP2011516417A (https=)
KR (1) KR20100135847A (https=)
CN (1) CN101977606A (https=)
AU (1) AU2009228660B2 (https=)
BR (1) BRPI0909378A2 (https=)
CA (1) CA2719749A1 (https=)
IL (1) IL207835A0 (https=)
MX (1) MX2010009649A (https=)
NZ (1) NZ588698A (https=)
RU (1) RU2499598C2 (https=)
WO (1) WO2009118187A1 (https=)
ZA (1) ZA201006587B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US11232319B2 (en) 2014-05-16 2022-01-25 The Trustees Of The University Of Pennsylvania Applications of automatic anatomy recognition in medical tomographic imagery based on fuzzy anatomy models
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
AU2016291158B2 (en) 2015-07-09 2020-04-30 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11000526B2 (en) 2016-11-22 2021-05-11 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US10732235B2 (en) * 2018-03-29 2020-08-04 Siemens Healthcare Gmbh Magnetic resonance method and apparatus using atlas-based masking for quantitative susceptibility mapping
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1131031C (zh) * 1996-03-08 2003-12-17 弗·哈夫曼-拉罗切有限公司 作为nmda受体亚型阻断剂的4－苯基3，6－二氢－2h－吡啶基衍生物的应用
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
ATE274494T1 (de) * 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US7022882B2 (en) * 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2009503520A (ja) * 2005-07-29 2009-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベータアミロイド受容体及びその使用

Also Published As

Publication number Publication date
JP2011516417A (ja) 2011-05-26
AU2009228660B2 (en) 2012-11-29
EP2254580A1 (en) 2010-12-01
CN101977606A (zh) 2011-02-16
RU2499598C2 (ru) 2013-11-27
BRPI0909378A2 (pt) 2015-10-06
AU2009228660A1 (en) 2009-10-01
MX2010009649A (es) 2010-12-17
US20110053951A1 (en) 2011-03-03
RU2010143864A (ru) 2012-05-10
WO2009118187A1 (en) 2009-10-01
KR20100135847A (ko) 2010-12-27
JP2016094430A (ja) 2016-05-26
JP2014098018A (ja) 2014-05-29
NZ588698A (en) 2012-06-29
IL207835A0 (en) 2010-12-30
ZA201006587B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CA2719749A1 (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
JP2011516417A5 (https=)
NZ589445A (en) Rasagiline for parkinson's disease modification
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2004087116A3 (es) Combinación de drogas para la disfunción motora en la enfermedad de parkinson
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ594264A (en) Treatment of dyskinesia related disorders
WO2008030830A3 (en) Sustained-release composition and method of use thereof
MX2014002460A (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
JP2008515801A5 (https=)
TW200613255A (en) Therapeutic diphenyl ether ligands

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140131

FZDE Discontinued

Effective date: 20170329